arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

MAIA Biotechnology, Inc.

MAIA

$1.32 ▼ -0.05 (-3.65%) at close

5 Visible periods

20 Metrics

Absolute Benchmarks

Price Chart

Health

Weak

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, MAIA Biotechnology, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $42.4M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -1021.6% ↘

FCF / Share $-0.59 ↗

Trailing P/E —

Price / Book 21.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-22.40M

↑ +3.7% —

FCF / Share Free cash flow per share

$-0.59

↑ +17.1% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -1021.6% is weak on an absolute basis (target > 10%)
FCF / Net IncomeFCF / Net Income of 0.84x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	33.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	29.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	14.9% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	26.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—
Net Income Growth YoY (%)	3.7% Caution ↑ Caution Improving Year-over-year change in net income	-17.6% Weak ↑ Weak Improving Year-over-year change in net income	-25.4% Weak Weak Year-over-year change in net income	-25.4% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	17.1% Good ↑ Good Improving Year-over-year change in free cash flow	28.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	21.6% Good Good Year-over-year change in free cash flow	-60.9% Weak Weak Year-over-year change in free cash flow	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Effective Tax Rate (%) (%)	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
FCF / Net Income (x)	0.84x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.33x Weak Weak Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-1021.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-466.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-250.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-167.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-266.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-134.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-68.7% Weak Weak Operating profit relative to total assets Optimal: > 10%

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Interest Coverage (x)	—	—	-2940.75x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-2321.83x Weak Weak Operating income divided by interest expense Optimal: > 5x	-9.41x Weak Weak Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	$0.00	$0.00	$0.00	$0.00	$0.00

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Revenue per Share (USD)	—	—	$0.00	$0.00	—
Basic EPS, GAAP (USD)	$-0.70	$-1.05	$-1.49	$-1.75	$-2.37
Free Cash Flow per Share (USD)	$-0.59	$-0.71	$-0.99	$-1.26	$-0.78
Book Value per Share (USD)	$0.06	$0.14	—	—	—
Tangible Book Value per Share (USD)	$0.06	$0.14	—	—	—
Basic Weighted Avg Shares (shares)	32.11M	22.20M	13.26M	9.28M	5.28M

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$3.87M	$6.32M	$2.63M	$8.54M	$8.53M
Total Equity (USD)	$2.38M	$3.63M	—	—	—

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	$0.00	$0.00	—
Net Income, GAAP (USD)	$-22.40M	$-23.25M	$-19.77M	$-15.77M	$-12.58M
Operating Cash Flow (USD)	$-18.84M	$-15.70M	$-13.07M	$-11.66M	$-4.12M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 5 years · 21 quarters

MAIA Biotechnology, Inc.

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare MAIA with peers